Trial Profile
Retrospective, Observational Evaluation of the Utilization, Outcomes, and Adverse Events Associated With Orbactiv for the Treatment of Infections Presumed or Confirmed to be Caused by Gram Positive Bacteria in a Real World Setting
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Mar 2018
Price :
$35
*
At a glance
- Drugs Oritavancin (Primary)
- Indications Gram-positive infections
- Focus Therapeutic Use
- Sponsors Melinta Therapeutics; The Medicines Company
- 08 Mar 2018 Status changed from active, no longer recruiting to completed.
- 13 Nov 2017 Planned End Date changed from 1 Oct 2017 to 1 Nov 2017.
- 13 Nov 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Nov 2017.